Kymera up after FDA fast-track for asthma pill

Kymera Therapeutics

13/04/2026 12:36

** Kymera Therapeutics KYMR.O shares rise 2% to $86.50 premarket

** Biotech firm says the United Stat5es Food and Drug Administration granted Fast Track status to KT-621, an experimental once-daily pill for moderate to severe eosinophilic asthma, a hard-to-treat form of asthma linked to high levels of airway inflammation

** Adds that KT-621 targets immune pathways that drive inflammation and aims to improve symptom control in patients who do not respond well to existing inhalers or injections

** Running a mid-stage trial in asthma with results expected in late 2027 and a separate mid-stage trial in atopic dermatitis, a chronic skin disease, with data due by mid-2027 - KYMR

** Fast-track status is meant to speed development and review of treatments for serious diseases with unmet medical need

** As of last close, stock up ~9% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))